On April 8th, Impel's director of business development, Paul Jenkins, will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Nasal Drug Delivery Conference in London. His presentation is on April 8 at 11:30 am in the Nose-to-brain Transport session....

On April 6 Impel CSO, John Hoekman will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Neurotech conference in Boston. His talk will be on April 6 at 10:30 at the Treatments for Alzheimer's and Cognitive Disorders session.  ...

SEATTLE February 29, 2016 -- The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. This novel treatment is a peptide that disrupts two dopamine receptors that bind at higher rates...

Seattle March 24, 2014 – A nasal spray that delivers a new type of depression treatment holds promise as a potential alternative therapeutic approach, research from the Centre for Addiction and Mental Health (CAMH) shows. The study, led by CAMH’s Dr. Fang Liu, is published online in Neuropsychopharmacology. In a previous study published...